Abstract:The nuclear enzyme topoisomerase I (topo I) has been recently recognized as the target for the anticancer drug camptothecin (CPT) and its derivatives. Two of the agents that target this enzyme--topotecan (TPT) and CPT-11--appear to be active against a broad range of human tumors. In the following presentation, we review 1) the role of topo I in normal cells, 2) the chemistry and proposed mechanism of action of CPT and its analogues, 3) the results of preclinical and clinical testing of TPT and CPT-11, and 4) mechanisms of resistance to these agents. In normal cells, topo I is thought to be involved in gene transcription and DNA replication. During the course of its normal catalytic cycle, topo I transiently forms a covalent bond with DNA. CPT and its derivatives slow the religation step of the enzyme and stabilize the covalent adduct between topo I and DNA. In S-phase cells, advancing replication forks convert these topo I-DNA adducts into double-strand breaks that appear to be responsible for the cytotoxicity of these agents. Preclinical studies demonstrate antineoplastic activity for TPT and CPT-11 in a variety of tumor models. Phase I studies have identified neutropenia as the dose-limiting toxicity for both drugs. Gastrointestinal effects might also be dose-limiting for CPT-11 administered on some schedules. CPT-11 has shown antitumor activity in phase II trials for patients with carcinomas of lung, cervix, ovary, colon, and rectum and for patients with non-Hodgkin's lymphoma. Phase II studies of TPT are in progress. Resistance to the cytotoxic effects of these agents might result from decreased production of topo I or from production of a mutated form of topo I. In addition, decreased metabolic activation of CPT-11 (which is a pro-drug) and active efflux of TPT by P-glycoprotein-mediated transport might contribute to resistance. As agents with a novel mechanism of action, tolerable toxicity, and encouraging antitumor activity in early clinical trials, TPT and CPT-11 are undergoing further clinical development. If these agents can be successfully combined with other active chemotherapy agents, the topo I-directed agents offer the potential for significant advances in the treatment of patients with a variety of malignancies.

Review camptothecin: current perspectives.

Perspectives on Biologically Active Camptothecin Derivatives

The current status of camptothecin analogues as antitumor agents.

Current status of CPT and its analogues in the treatment of malignancies

Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?

Camptothecin and its derivatives: Advancements, mechanisms and clinical potential in cancer therapy

Unleashing the Potential of Camptothecin: Exploring Innovative Strategies for Structural Modification and Therapeutic Advancements

Evolution in medicinal chemistry of E-ring-modified Camptothecin analogs as anticancer agents.

Two Novel Camptothecin Derivatives Inhibit Colorectal Cancer Proliferation Via Induction of Cell Cycle Arrest and Apoptosis in Vitro and in Vivo

Research on Camptothecine (CPT) and its Derivative

Topoisomerase I inhibitors: Review and update

Progress on the Functional Modification of the Anticancer Drug:Camptothecin

[A symphony for the camptothecins]

Design and One-Pot Synthesis of New 7-Acyl Camptothecin Derivatives As Potent Cytotoxic Agents

Camptothecin's journey from discovery to WHO Essential Medicine: Fifty years of promise

New Homocamptothecins: Synthesis, Antitumor Activity, and Molecular Modeling.

Synthesis and Antitumor Activity of Novel 10-Substituted Camptothecin Analogues.

Topoisomerase I-mediated antiproliferative activity of 10-substituted and 12-substituted homocamptothecins

Synthesis and biological evaluation of novel homocamptothecins conjugating with dihydropyrimidine derivatives as potent topoisomerase I inhibitors

Design and Synthesis of Novel 7-[(N-substituted-thioureidopiperazinyl)-methyl]-camptothecin Derivatives As Potential Cytotoxic Agents.

Camptothecin-based prodrug nanomedicines for cancer therapy